Literature DB >> 2579881

Rheumatoid factor-like reactants in sera proven to transmit non-A, non-B hepatitis: a potential source of false-positive reactions in non-A, non-B assays.

H Shiraishi, H J Alter, S M Feinstone, R H Purcell.   

Abstract

Convalescent phase non-A, non-B (NANB) human and chimpanzee sera were utilized in a solid-phase radioimmunoassay (RIA) in an attempt to identify a specific NANB antigen in human plasma, plasma-derived pellets and NP-40 disrupted pellets proven to transmit NANB infection to chimpanzees. RIA reactivity was noted in 5 of 8 pedigreed NANB infectious plasmas, but did not appear to be virus-specific. The RIA reactive fraction: (i) had a density of 1.27 to 1.32 gm per cm3 in cesium chloride; (ii) showed immunoreactivity corresponding to normal IgM, but peak RIA activity coincided with an aberrant IgM having a peak sedimentation coefficient of 56 S, and (iii) eluted at higher pH (5.6 to 5.0) than normal IgM on chromatofocusing columns. The reactant shared properties with rheumatoid factor in that it was absorbed by aggregated IgG and was unstable to 2-mercaptoethanol, but it did not react in standard agglutination tests for rheumatoid factor. The reactant was detected in both the acute and chronic phase of NANB infections in chimpanzee and man. By reacting with IgG in presumptive NANB convalescent sera, this aberrant rheumatoid factor could simulate a NANB antigen and represent a cause of false-positive reactions in putative NANB assays.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579881     DOI: 10.1002/hep.1840050204

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  1 in total

1.  Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.

Authors:  Joyce S Lee; Eunice J Kim; Kara L Lynch; Brett Elicker; Christopher J Ryerson; Tamiko R Katsumoto; Anthony K Shum; Paul J Wolters; Stefania Cerri; Luca Richeldi; Kirk D Jones; Talmadge E King; Harold R Collard
Journal:  Respir Med       Date:  2012-11-24       Impact factor: 3.415

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.